SGMO Sangamo Therapeutics Inc

Price (delayed)

$6.33

Market cap

$990.98M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.17

Enterprise value

$913.31M

Sangamo Therapeutics is committed to translating ground-breaking science into genomic medicines with the potential to transform patients' lives using gene therapy, cell therapy, and genome engineering.

Highlights
Sangamo Therapeutics's net income has decreased by 27% YoY but it has increased by 2.3% QoQ
The EPS has declined by 23% year-on-year but it is up by 3.3% since the previous quarter
The quick ratio has declined by 32% year-on-year and by 2.2% since the previous quarter
The equity fell by 29% YoY and by 4.9% QoQ

Key stats

What are the main financial stats of SGMO
Market
Shares outstanding
156.55M
Market cap
$990.98M
Enterprise value
$913.31M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
2.92
Price to sales (P/S)
8.22
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
8
Earnings
Revenue
$114.16M
EBIT
-$172.18M
EBITDA
-$152.78M
Free cash flow
-$241.44M
Per share
EPS
-$1.17
Free cash flow per share
-$1.63
Book value per share
$2.17
Revenue per share
$0.77
TBVPS
$3.58
Balance sheet
Total assets
$617.13M
Total liabilities
$298.85M
Debt
$41.53M
Equity
$318.28M
Working capital
$223.13M
Liquidity
Debt to equity
0.13
Current ratio
2.86
Quick ratio
2.69
Net debt/EBITDA
0.51
Margins
EBITDA margin
-133.8%
Gross margin
100%
Net margin
-151%
Operating margin
-157.1%
Efficiency
Return on assets
-24.9%
Return on equity
-48.1%
Return on invested capital
-47%
Return on capital employed
-34.6%
Return on sales
-150.8%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

SGMO stock price

How has the Sangamo Therapeutics stock price performed over time
Intraday
8.76%
1 week
21.73%
1 month
41.29%
1 year
-38%
YTD
-15.6%
QTD
52.9%

Financial performance

How have Sangamo Therapeutics's revenue and profit performed over time
Revenue
$114.16M
Gross profit
$114.16M
Operating income
-$179.33M
Net income
-$172.33M
Gross margin
100%
Net margin
-151%
SGMO's net margin has shrunk by 54% YoY but it is up by 3.5% QoQ
SGMO's operating margin has dropped by 52% year-on-year but it is up by 2.9% since the previous quarter
Sangamo Therapeutics's net income has decreased by 27% YoY but it has increased by 2.3% QoQ
The operating income has contracted by 26% YoY

Growth

What is Sangamo Therapeutics's growth rate over time

Valuation

What is Sangamo Therapeutics stock price valuation
P/E
N/A
P/B
2.92
P/S
8.22
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
8
The EPS has declined by 23% year-on-year but it is up by 3.3% since the previous quarter
The equity fell by 29% YoY and by 4.9% QoQ
The price to book (P/B) is 21% lower than the 5-year quarterly average of 3.7 but 12% higher than the last 4 quarters average of 2.6
The stock's P/S is 50% below its 5-year quarterly average of 16.4 and 6% below its last 4 quarters average of 8.7
The revenue is down by 17% year-on-year

Efficiency

How efficient is Sangamo Therapeutics business performance
Sangamo Therapeutics's return on invested capital has shrunk by 87% YoY and by 7% QoQ
The ROE has plunged by 72% YoY and by 6% from the previous quarter
The company's return on assets has shrunk by 66% YoY and by 6% QoQ
The return on sales has dropped by 54% year-on-year but it is up by 3.6% since the previous quarter

Dividends

What is SGMO's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for SGMO.

Financial health

How did Sangamo Therapeutics financials performed over time
SGMO's total assets is 107% greater than its total liabilities
The quick ratio has declined by 32% year-on-year and by 2.2% since the previous quarter
The company's current ratio fell by 29% YoY
SGMO's debt is 87% lower than its equity
Sangamo Therapeutics's debt to equity has surged by 63% YoY
The equity fell by 29% YoY and by 4.9% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.